Benjamin L. Handen, Mark Mapstone, Sigan Hartley, Howard Andrews, Brad Christian, Joseph H. Lee, Dana Tudorascu, Christy Hom, Beau M. Ances, Shahid Zaman, Sharon Krinsky-McHale, Adam M. Brickman, H. Diana Rosas, Annie Cohen, Melissa Petersen, Sid O'Bryant, Jordan P. Harp, Frederick Schmitt, Lauren Ptomey, Jeffrey Burns, Ira T. Lott, Florence Lai, Wayne Silverman, Charles Laymon, Elizabeth Head, the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)
{"title":"The Alzheimer's Biomarker Consortium–Down Syndrome (ABC-DS): A 10-year report","authors":"Benjamin L. Handen, Mark Mapstone, Sigan Hartley, Howard Andrews, Brad Christian, Joseph H. Lee, Dana Tudorascu, Christy Hom, Beau M. Ances, Shahid Zaman, Sharon Krinsky-McHale, Adam M. Brickman, H. Diana Rosas, Annie Cohen, Melissa Petersen, Sid O'Bryant, Jordan P. Harp, Frederick Schmitt, Lauren Ptomey, Jeffrey Burns, Ira T. Lott, Florence Lai, Wayne Silverman, Charles Laymon, Elizabeth Head, the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)","doi":"10.1002/alz.70294","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Virtually all adults with Down syndrome (DS) will accumulate the neuropathologies associated with Alzheimer's disease (AD) by age 40, with the majority having a clinical dementia diagnosis by their middle 50s.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>This paper complements a 2020 publication describing the Alzheimer's Biomarker Consortium–Down Syndrome (ABC-DS) methodology by highlighting protocol changes since initial funding in 2015. It describes available clinical, neuropsychological, neuroimaging, and biofluid data and bio-specimen repository. Ten years of accomplishments are summarized.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow-up visits. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>ABC-DS is the largest U.S.-based, multi-site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The Alzheimer's Biomarker Consortium—Down Syndrome (ABC-DS) is entering its 10th year.</li>\n \n <li>Over 500 adults with Down syndrome (DS) and 59 sibling controls have been enrolled.</li>\n \n <li>More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted.</li>\n \n <li>Multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples.</li>\n \n <li>It is positioned to continue to make substantial contributions to the DS field.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 5","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70294","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70294","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Virtually all adults with Down syndrome (DS) will accumulate the neuropathologies associated with Alzheimer's disease (AD) by age 40, with the majority having a clinical dementia diagnosis by their middle 50s.
METHODS
This paper complements a 2020 publication describing the Alzheimer's Biomarker Consortium–Down Syndrome (ABC-DS) methodology by highlighting protocol changes since initial funding in 2015. It describes available clinical, neuropsychological, neuroimaging, and biofluid data and bio-specimen repository. Ten years of accomplishments are summarized.
RESULTS
Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow-up visits. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples.
DISCUSSION
ABC-DS is the largest U.S.-based, multi-site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD.
Highlights
The Alzheimer's Biomarker Consortium—Down Syndrome (ABC-DS) is entering its 10th year.
Over 500 adults with Down syndrome (DS) and 59 sibling controls have been enrolled.
More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted.
Multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples.
It is positioned to continue to make substantial contributions to the DS field.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
